Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary

Ultragenyx Pharmaceutical

05/08/2026 24:04

Ultragenyx Pharmaceutical Inc RARE.OQ reported a quarterly adjusted loss of 90 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.17.  The mean expectation of eighteen analysts for the quarter was for a loss of $1.22 per share. Wall Street expected results to range from $-1.42 to -78 cents per share.
Revenue rose 28.5% to $214.00 million from a year ago; analysts expected $182.70 million. 
Ultragenyx Pharmaceutical Inc's reported EPS for the quarter was a loss of 90 cents​.
The company reported a quarterly loss of $92 million.
Ultragenyx Pharmaceutical Inc shares had fallen by 25.1% this quarter and gained 8.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.5% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc. is $47.50, about 45.7% above its last closing price of $25.81
This summary was machine generated from LSEG data August 4 at 11:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.22
-0.90
Beat
Mar. 31 2026 
-1.51
-1.84
Missed
Dec. 31 2025 
-1.09
-1.29
Missed
Sep. 30 2025 
-1.23
-1.81
Missed